157 related articles for article (PubMed ID: 33363254)
1. Natural Products Database Screening for the Discovery of Naturally Occurring SARS-Cov-2 Spike Glycoprotein Blockers.
Al-Sehemi AG; Olotu FA; Dev S; Pannipara M; Soliman ME; Carradori S; Mathew B
ChemistrySelect; 2020 Nov; 5(42):13309-13317. PubMed ID: 33363254
[TBL] [Abstract][Full Text] [Related]
2. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of SARS-CoV-2 Spike Protein via Natural Compounds: A Multilayered High Throughput Virtual Screening Approach.
Dhasmana A; Kashyap VK; Dhasmana S; Kotnala S; Haque S; Ashraf GM; Jaggi M; Yallapu MM; Chauhan SC
Curr Pharm Des; 2020; 26(41):5300-5309. PubMed ID: 32867645
[TBL] [Abstract][Full Text] [Related]
4. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.
Khursheed A; Jain V; Rasool A; Rather MA; Malik NA; Shalla AH
Microb Pathog; 2021 Aug; 157():104933. PubMed ID: 33984466
[TBL] [Abstract][Full Text] [Related]
5. Antiviral Efficacy of Selected Natural Phytochemicals against SARS-CoV-2 Spike Glycoprotein Using Structure-Based Drug Designing.
Aloufi BH; Snoussi M; Sulieman AME
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458599
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach.
Mathew SM; Benslimane F; Althani AA; Yassine HM
Qatar Med J; 2021; 2021(1):12. PubMed ID: 34604010
[No Abstract] [Full Text] [Related]
7. Systematic virtual screening in search of SARS CoV-2 inhibitors against spike glycoprotein: pharmacophore screening, molecular docking, ADMET analysis and MD simulations.
Dhameliya TM; Nagar PR; Gajjar ND
Mol Divers; 2022 Oct; 26(5):2775-2792. PubMed ID: 35132518
[TBL] [Abstract][Full Text] [Related]
8. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
9. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.
Kadioglu O; Saeed M; Greten HJ; Efferth T
Comput Biol Med; 2021 Jun; 133():104359. PubMed ID: 33845270
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease.
Oso BJ; Olaoye IF; Omeike SO
Arch Razi Inst; 2021; 76(3):453-459. PubMed ID: 34824739
[TBL] [Abstract][Full Text] [Related]
12. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
13. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Romeo A; Iacovelli F; Falconi M
Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
[TBL] [Abstract][Full Text] [Related]
14. Small Molecules Targeting SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain.
RodrÃguez Y; Cardoze SM; Obineche OW; Melo C; Persaud A; Fernández Romero JA
ACS Omega; 2022 Aug; 7(33):28779-28789. PubMed ID: 35991504
[TBL] [Abstract][Full Text] [Related]
15. The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms.
Paiardi G; Richter S; Oreste P; Urbinati C; Rusnati M; Wade RC
J Biol Chem; 2022 Feb; 298(2):101507. PubMed ID: 34929169
[TBL] [Abstract][Full Text] [Related]
16. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
[TBL] [Abstract][Full Text] [Related]
17. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.
Naik B; Gupta N; Ojha R; Singh S; Prajapati VK; Prusty D
Int J Biol Macromol; 2020 Oct; 160():1-17. PubMed ID: 32470577
[TBL] [Abstract][Full Text] [Related]
18. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
20. Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19.
Ma LL; Liu HM; Liu XM; Yuan XY; Xu C; Wang F; Lin JZ; Xu RC; Zhang DK
Eur J Med Chem; 2021 Dec; 226():113857. PubMed ID: 34628234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
